Showing results (121-130 of 167) with videos related to
Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancerJ Nemunaitis, J T Holmlund, M Kraynak, et al.Cancer Research|December 5, 2000
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trialJ Nemunaitis, I Ganly, F Khuri, et al.Blood|August 1, 1987
Simian virus 40-transformed adherent cells from human long-term marrow cultures: cloned cell lines produce cells with stromal and hematopoietic characteristicsJ W Singer, P Charbord, A Keating, et al.Gene Therapy|March 8, 2013
Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccineJ Nemunaitis, N Senzer, J Olivares, et al.American Journal of Hematology|April 1, 1996
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatinJ C Yau, J A Neidhart, P Triozzi, et al.Cancer Immunology, Immunotherapy : CII|April 29, 2014
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapyDavid A Smith, Paul Conkling, Donald A Richards, et al.Blood|June 15, 1994
Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemiaJ Nemunaitis, F R Appelbaum, K Lilleby, et al.Cancer Biology & Therapy|June 25, 2013
Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancerChandra P Belani, John J Nemunaitis, Abraham Chachoua, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studiesJ Nemunaitis, C Poole, J Primrose, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerEric J Small, Paul F Schellhammer, Celestia S Higano, et al.Pageof 17